Experienced in WT1-Related Wilms Tumor Syndromes

Ali A. Bazarbachi

Beirut, BA, LB 
Experienced in WT1-Related Wilms Tumor Syndromes
Beirut, BA, LB 
OverviewLocationsClinical Research

Overview

Ali Bazarbachi practices in Beirut, Lebanon. Bazarbachi is rated as an Experienced expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Their top areas of expertise are Leukemia, Adult T-Cell Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Graft.

Their clinical research consists of co-authoring 322 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of WT1-Related Wilms Tumor Syndromes.

Locations

Beirut, BA, Lebanon

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia
Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Phase: Not Applicable
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Other
Nutrition Intervention Among Stem Cell Recipients: a Randomized Controlled Trial Post Hospital Discharge
Nutrition Intervention Among Stem Cell Recipients: a Randomized Controlled Trial Post Hospital Discharge
Enrollment Status: Completed
Publish Date: February 08, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 2 Less Clinical Trials

322 Total Publications

Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry.
Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry.
Journal: Bone marrow transplantation
Published: July 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bazarbachi's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile